Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Business Insights | The US Pharmaceutical Market Outlook To 2014: Market trends, leading players and forecasts

The US Pharmaceutical Market Outlook To 2014: Market trends, leading players and forecasts

The US healthcare system involves a multitude of stakeholders; a mix of public and private players. The government funds healthcare for certain sections of the society while majority of the population has a private health insurance sponsored by employers. Pharmaceutical manufacturers in the US are relatively free to set their own prices for drugs which tend to be, on an average, two to three times higher than in Europe. The US market in general works by administering reimbursement controls rather than price controls. Instead of a direct price control, the government is known to have been using tacit persuasion tactics, on grounds of morality, to convince drug companies to slash prices. However the scenario is changing in light of a growing demand for administering direct price controls. The report provides analysis on the performance of key brands in a range of major indications in the US pharmaceutical market, including central nervous system disorders, cancer, cardiovascular diseases and metabolic disorders. The report also incorporates analysis of the portfolios and pipelines of the leading pharmaceutical companies active in the US market today.

Published: June 2009 - US.

Table of Contents
Price: $3,835.00 / €2,565.62

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions